%0 Journal Article %A C. Brandon Ogbunugafor %A Miles D. Miller-Dickson %A Victor A. Meszaros %A Lourdes M. Gomez %A Anarina L. Murillo %A Samuel V. Scarpino %T Variation in SARS-CoV-2 free-living survival and environmental transmission can modulate the intensity of emerging outbreaks %D 2020 %R 10.1101/2020.05.04.20090092 %J medRxiv %P 2020.05.04.20090092 %X Variation in free-living, microparasite survival can have a meaningful impact on the ecological dynamics of established and emerging infectious diseases. Nevertheless, resolving the importance of environmental transmission in the ecology of epidemics remains a persistent challenge, requires accurate measuring the free-living survival of pathogens across reservoirs of various kinds, and quantifying the extent to which interaction between hosts and reservoirs generates new infections. These questions are especially salient for emerging pathogens, where sparse and noisy data can obfuscate the relative contribution of different infection routes. In this study, we develop a mechanistic, mathematical model that permits both direct (host-to-host) and indirect (environmental) transmission and then fit this model to empirical data from 17 countries affected by an emerging virus (SARS-CoV-2). From an ecological perspective, our model highlights the potential for environmental transmission to drive complex, non-linear dynamics during infectious disease outbreaks. Summarizing, we propose that fitting such models with environmental transmission to real outbreak data from SARS-CoV-2 transmission highlights that variation in environmental transmission is an underappreciated aspect of the ecology of infectious disease, and an incomplete understanding of its role has consequences for public health interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementALM would like to acknowledge NIH U54GM115677 for funding support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NoneAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are either available or the source is referenced in the main text and supplemental information. The code used for the analyses in this study is publicly available on Github: https://github.com/OgPlexus/Copperland https://github.com/OgPlexus/Copperland %U https://www.medrxiv.org/content/medrxiv/early/2020/08/01/2020.05.04.20090092.full.pdf